Healthcare / Medical Instruments & SuppliesNasdaqCM
$5.50
+0.06 (+1.10%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-3.0M · quality 59.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$60M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-47.2%
↓Gross Margin
17.8%
↓Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
+16.5%
FCF CAGR
—
FCF margin
-19.8%
FCF / Net income
0.65x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $19.1M · net income $-5.8M · FCF $-3.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $19.1M | $19.1M | $19.1M | $21.0M | $15.7M | $10.7M | $9.9M | $6.8M | $4.0M | $3.2M | $3.9M | $3.9M | $3.7M | $2.5M | $2.2M | $2.2M |
| Net Income | $-5.8M | $-5.8M | $-3.0M | $-144613.00 | $-928416.00 | $-102835.00 | $-1.4M | $-614871.00 | $-351390.00 | $-1.0M | $-1.0M | $-1.2M | $-1.2M | $-1.8M | $960972.00 | $-1.1M |
| EBITDA | $-5.3M | $-5.3M | $-2.5M | $286985.00 | $-581585.00 | $-758784.00 | $-1.3M | $-573989.00 | $-321403.00 | $-968741.00 | $-1.0M | $-1.2M | $-1.1M | $-1.2M | $-1.3M | $-934303.00 |
| EPS | -0.85 | -0.85 | -0.49 | -0.03 | -0.18 | -0.03 | — | -0.15 | -0.12 | -0.36 | -0.45 | -0.57 | -0.78 | -1.53 | 2.34 | -3.18 |
| Gross Margin | 17.8% | 17.8% | 30.3% | 36.8% | 31.4% | 32.2% | 33.9% | 31.2% | 36.7% | 24.5% | 24.1% | 20.4% | 21.9% | 26.0% | 25.9% | 33.5% |
| Operating Margin | -29.1% | -29.1% | -14.3% | -3.0% | -8.6% | -8.5% | -14.3% | -9.0% | -8.6% | -31.8% | -26.9% | -31.0% | -31.8% | -48.9% | -59.7% | -44.2% |
| Net Margin | -30.3% | -30.3% | -15.4% | -0.7% | -5.9% | -1.0% | -14.4% | -9.0% | -8.7% | -31.9% | -26.4% | -30.1% | -31.8% | -70.9% | 44.6% | -46.9% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.17 | 0.17 | 0.34 | 0.26 | 0.33 | 0.00 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 2.10 | 2.10 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-3.8M | $-3.8M | $-3.0M | $-133587.00 | $-1.1M | $-29374.00 | $-711642.00 | $-1.2M | $96209.00 | $-695153.00 | $-880670.00 | — | — | $-1.3M | $-1.6M | — |
| Returns | ||||||||||||||||
| ROE | -47.2% | -47.2% | -29.3% | -1.2% | -10.3% | -3.0% | -51.5% | -18.2% | -62.3% | -180.2% | -176.2% | -176.8% | -156.7% | -104.5% | 185.0% | 88.1% |
| Valuation | ||||||||||||||||
| EV/EBITDA | — | — | — | 117.89 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 3.05 | 3.05 | 3.78 | 2.79 | 3.79 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | -0.1% | -0.1% | -9.2% | 34.2% | — | 7.6% | 45.8% | 68.5% | 28.0% | -19.5% | 0.1% | 7.1% | 44.9% | 17.1% | -4.1% | — |
| EPS Growth | -73.5% | -73.5% | -1533.3% | 83.3% | — | — | — | -25.0% | 66.7% | 20.0% | 21.1% | 26.9% | 49.0% | -165.4% | 173.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+27.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.49 → -0.85
Residual
+27.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.